A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block
Status:
Completed
Trial end date:
2017-11-17
Target enrollment:
Participant gender:
Summary
The objective of this pivotal study is to evaluate the relative bioavailability of SYN010 HFA
Inhaler and Symbicort 160/4.5μg in healthy volunteers without charcoal block.